Q1 2025 Rossari Biotech Ltd Earnings Call Transcript
Key Points
- Rossari Biotech Ltd (BOM:543213) reported a strong start to FY25 with a 19.3% year-on-year revenue growth and a 19.5% increase in profit.
- The SPPC segment achieved a robust 21% growth, and the textile specialty chemicals division also saw a 21% growth.
- The company is experiencing notable success in export markets, which are growing faster than domestic markets.
- Recent expansions at Dahej and increased ethoxylation capacity are expected to meet growing demand across key segments.
- Rossari Biotech Ltd (BOM:543213) continues to focus on R&D, driving innovation and creating sustainable value for stakeholders.
- The AHN division faced challenges due to industry headwinds, resulting in flat performance.
- EBITDA margin dropped to 13.3% from 14.1% in the previous year, primarily due to increased other expenses.
- Higher freight, travel, maintenance, and selling and distribution costs contributed to increased expenses.
- The company faces industry-wide issues with IGST refund claims, which could potentially impact financials.
- Working capital days have been increasing, and the company expects this to be the new normal due to the nature of the surfactant business.
Ladies and gentlemen, good day and welcome to the Rossari Biotech Limited earnings conference call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Mr. Anoop Poojari from CDR India. Thank you, and over to you, Mr. Poojari.
Thank you. Good evening, everyone, and thank you for joining us on Rossari Biotech's Q1 FY25 earnings conference call. We have with us Mr. Edward Menezes, Promoter and Executive Chairman; Mr. Sunil Chari, Promoter and Managing Director, and Mr. Ketan Sablok, Group Chief Financial Officer of the company. We'll begin the call with opening remarks from the management, following which we'll have the forum open for a question-and-answer session.
Before we start, I would like to point out that some statements made in today's call may be forward-looking in nature, and a disclaimer to this effect has been included in the earnings presentation shared with you earlier.
I would now like to invite Mr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
